Showing 981 - 1,000 results of 104,605 for search '(( 5 ((a decrease) OR (mean decrease)) ) OR ( 50 ((we decrease) OR (nn decrease)) ))', query time: 0.90s Refine Results
  1. 981

    Ophthalmic administration of CXCR3 antagonist decreases intraocular pressure in a rat model of ocular hypertension. by Alexandre Denoyer (160189)

    Published 2012
    “…<p><i>(A)</i> A single administration of CXCR3 antagonist (NBI-74330, 1 µM, 100 µL) induces a transient decrease in intraocular pressure (n = 10 in each group). …”
  2. 982
  3. 983

    Decrease in extracellular Zn<sup>2+</sup> in the hippocampus by zinc chelators. by Atsushi Takeda (18203)

    Published 2013
    “…<p>Hippocampal slices were prepared 2 h after i.p. injection of vehicle (A, n = 7) or CQ (30 mg/kg, B, n = 5) into NER, and 3 h after i.p. injection of vehicle (C, n = 7) or TPEN (1 mg/kg, D, n = 8) into NER. …”
  4. 984

    N100 amplitude decrease during 1 Hz-rTMS. by Christian Helfrich (297785)

    Published 2013
    “…<p>(<b>A</b>) N100 amplitude reduction during 1 Hz-rTMS (group mean values). …”
  5. 985
  6. 986
  7. 987
  8. 988
  9. 989
  10. 990

    Decreased Aβ42 halo overlaps with the decreased incidence of DNs in FO treated mice. by Milena Jović (6707702)

    Published 2019
    “…(E-H) In the FO-treated 5xFAD animals the decreased surface of the Aβ halo overlaps with the decreased incidence of swollen, dystrophic neurites.…”
  11. 991

    Capzb2 coimmunoprecipitates with βIII-tubulin in brain lysates and decreases tubulin polymerization in vitro. by David A. Davis (239142)

    Published 2009
    “…(E) Capzb2 decreases the rate and the extent of tubulin polymerization in a concentration-dependent manner. …”
  12. 992
  13. 993
  14. 994
  15. 995
  16. 996
  17. 997
  18. 998
  19. 999
  20. 1000

    Inhibition of SHP-2 activity decreases <i>C</i>. <i>parvum</i> infectivity. by Eunice A. Varughese (824701)

    Published 2015
    “…<p>A) Dose-dependent decrease of Infections per field of view (y-axis) after treatment of FHs 74 Int cells with increasing concentrations of the SHP-2-specific inhibitor, SHP-2 PTPase Inhibitor. …”